Lifecore Biomedical Inc (LFCR) Stock: Evaluating the Market Performance

Moreover, the 36-month beta value for LFCR is 1.05. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for LFCR is 29.63M and currently, short sellers hold a 5.93% of that float. On April 04, 2024, LFCR’s average trading volume was 200.05K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

LFCR) stock’s latest price update

Lifecore Biomedical Inc (NASDAQ: LFCR)’s stock price has gone rise by 11.41 in comparison to its previous close of 5.52, however, the company has experienced a 19.19% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-21 that Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.

LFCR’s Market Performance

Lifecore Biomedical Inc (LFCR) has experienced a 19.19% rise in stock performance for the past week, with a -24.82% drop in the past month, and a -3.61% drop in the past quarter. The volatility ratio for the week is 9.03%, and the volatility levels for the past 30 days are at 7.31% for LFCR. The simple moving average for the past 20 days is -6.31% for LFCR’s stock, with a -20.99% simple moving average for the past 200 days.

Analysts’ Opinion of LFCR

Many brokerage firms have already submitted their reports for LFCR stocks, with Stephens repeating the rating for LFCR by listing it as a “Equal-Weight.” The predicted price for LFCR in the upcoming period, according to Stephens is $2 based on the research report published on March 20, 2023 of the previous year 2023.

LFCR Trading at -14.35% from the 50-Day Moving Average

After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.31% of loss for the given period.

Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 9.03%, as shares sank -21.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.82% lower at present.

During the last 5 trading sessions, LFCR rose by +19.19%, which changed the moving average for the period of 200-days by -28.07% in comparison to the 20-day moving average, which settled at $6.48. In addition, Lifecore Biomedical Inc saw -0.65% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for LFCR

Current profitability levels for the company are sitting at:

  • -0.18 for the present operating margin
  • 0.22 for the gross margin

The net margin for Lifecore Biomedical Inc stands at -0.65. The total capital return value is set at -0.08. Equity return is now at value -116.16, with -26.37 for asset returns.

Based on Lifecore Biomedical Inc (LFCR), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at -61.21. The interest coverage ratio of the stock is -1.22.

Currently, EBITDA for the company is -11.12 million with net debt to EBITDA at -9.16. When we switch over and look at the enterprise to sales, we see a ratio of 2.87. The receivables turnover for the company is 3.3for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.39.

Conclusion

To wrap up, the performance of Lifecore Biomedical Inc (LFCR) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts